| 수집원 | 발생값 ↓ | 관측 가능 시각 | 법인 | 회사명 | 사업연도 | 기간 | 연결구분 | 재무제표 | 계정명 | 표준 지표 | 금액 | 기준일 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | CFS | BS | 자본금 | capital_stock | 1779.3억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | CFS | BS | 이익잉여금 | retained_earnings | 5.4조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | CFS | BS | 자본총계 | total_equity | 11.2조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | CFS | IS | 매출액 | revenue | 1.2조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | CFS | IS | 영업이익 | operating_income | 4866.8억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | CFS | IS | 법인세차감전 순이익 | pretax_income | 4993.8억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | CFS | IS | 당기순이익(손실) | net_income | 3755.5억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | CFS | IS | 총포괄손익 | comprehensive_income | 3754.3억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | OFS | BS | 유동자산 | current_assets | 3.6조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | OFS | BS | 비유동자산 | non_current_assets | 9.7조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | OFS | BS | 자산총계 | total_assets | 13.3조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | OFS | BS | 유동부채 | current_liabilities | 2.4조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | OFS | BS | 비유동부채 | non_current_liabilities | 1.3조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | OFS | BS | 부채총계 | total_liabilities | 3.7조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | OFS | BS | 자본금 | capital_stock | 1779.3억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | OFS | BS | 이익잉여금 | retained_earnings | 3.7조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | OFS | IS | 총포괄손익 | comprehensive_income | 1662.5억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | OFS | IS | 당기순이익(손실) | net_income | 1665.7억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | OFS | IS | 법인세차감전 순이익 | pretax_income | 2030.2억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | OFS | IS | 영업이익 | operating_income | 1364.2억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | OFS | IS | 매출액 | revenue | 6340억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | OFS | BS | 자본총계 | total_equity | 17.3조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | OFS | BS | 이익잉여금 | retained_earnings | 4.3조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | OFS | BS | 자본금 | capital_stock | 2308억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | OFS | BS | 부채총계 | total_liabilities | 2.7조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | OFS | BS | 비유동부채 | non_current_liabilities | 1399.5억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | OFS | BS | 유동부채 | current_liabilities | 2.6조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | OFS | BS | 자산총계 | total_assets | 20조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | OFS | BS | 비유동자산 | non_current_assets | 14.9조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | OFS | BS | 유동자산 | current_assets | 5.1조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | CFS | IS | 총포괄손익 | comprehensive_income | 1086.2억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | CFS | IS | 당기순이익(손실) | net_income | 1083.3억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | CFS | IS | 법인세차감전 순이익 | pretax_income | 1954.8억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | CFS | IS | 영업이익 | operating_income | 1494.2억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | CFS | IS | 매출액 | revenue | 8419.1억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | CFS | BS | 자본총계 | total_equity | 17.2조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | CFS | BS | 이익잉여금 | retained_earnings | 3.6조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | CFS | BS | 자본금 | capital_stock | 2308억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | CFS | BS | 부채총계 | total_liabilities | 3.6조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | CFS | BS | 비유동부채 | non_current_liabilities | 2747.7억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | CFS | BS | 유동부채 | current_liabilities | 3.4조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | CFS | BS | 자산총계 | total_assets | 20.9조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | CFS | BS | 비유동자산 | non_current_assets | 15.4조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:01 | — | 셀트리온 | 2,025 | Q1 | CFS | BS | 유동자산 | current_assets | 5.4조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | OFS | BS | 자본총계 | total_equity | 9.5조원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | OFS | IS | 매출액 | revenue | 9995.4억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | OFS | IS | 영업이익 | operating_income | 4300.1억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | OFS | IS | 법인세차감전 순이익 | pretax_income | 4232.3억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | OFS | IS | 당기순이익(손실) | net_income | 3195.7억원 | 2025-03-31 |
| dart-financials | 2025-05-15 | 2026-07-23 20:12:06 | — | 삼성바이오로직스 | 2,025 | Q1 | OFS | IS | 총포괄손익 | comprehensive_income | 3190.4억원 | 2025-03-31 |